Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

ERCC1 as a Biological Marker Guiding Management in Malignant Pleural Mesothelioma

  • Cihan, Yasemin Benderli (Department of Radiation Oncology, Kayseri Education and Research Hospital) ;
  • Ozturk, Ahmet (Department of Biostatistics, Erciyes University Medical School) ;
  • Arslan, Alaettin (Department of Radiation Oncology, Kayseri Education and Research Hospital) ;
  • Deniz, Kemal (Department of Pathology, Erciyes University Medical School) ;
  • Baran, Munevver (Department of Pathology, Erciyes University Medical School) ;
  • Karaca, Halit (Department of Medical Oncology, Erciyes University Medical School)
  • Published : 2014.05.30
Download PDF
⟨ Previous Next ⟩

Abstract

Background: To determine prognostic value of excision repair cross-complementation 1 (ERCC1) in patients with malignant pleural mesothelioma (MPM). Materials and Methods: The study included 60 patients with MPM who were diagnosed and treated in the Radiation Oncology Department of Kayseri Teaching Hospital and Medical Oncology Department of Erciyes University, Medicine School between 2005 and 2013. By using immunohistochemical methods, ERCC1 expression in biopsy specimens was evaluated. We retrospectively assessed whether there is a correlation between ERCC1 and response to anti-neoplastic therapy or survival. Results: There were 50 men and 10 women with median age of 62 years (range: 39-83). Histological type was epithelial mesothelioma in the majority of the cases (85%), most commonly presenting in stage four. Of the cases, 20 (33%) received radiotherapy, 60 (%100) received first-line chemotherapy and 15 (%25) received second-line chemotherapy. In the assessment after therapy, it was found that there was partial response in 12 cases (20%), stable disease in 19 cases (31.4%) and progression in 25 cases (41.7%). ERCC1 was positive in 43% of the cases. Mean OS was 11.7 months and mean DFS was 9.5 months in ERCC1-positive cases regardless of therapy, while they were 19.2 months and 17.1 months in ERCC1-negative cases, respectively. The difference was found to be significant (p<0.05). In univariate analysis, stage, comorbidity, response to treatment and ERCC1 expression were found to be significantly associated with OS (p=0.083; p=0.043; p=0.041; p=0.050). In multivariate analysis, response to treatment remained to be significant for OS (p=0.005). In univariate and multivariate analyses, response to treatment and ERCC1 were found to be significantly associated with DFS (p=0.049; p=0.041). Conclusions: ERCC1 was identified as poor prognostic factor in patients with MPM.

Keywords

References

  1. Betti M, Ferranteb D, Padoanb M, et al (2011). XRCC1 and ERCC1 variants modify malignant mesothelioma risk: A case-control study. Mutat Res, 708, 11-20. https://doi.org/10.1016/j.mrfmmm.2011.01.001
  2. Ceppi P, Volante M, Novello S, et al (2006). ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol, 17, 1818-25. https://doi.org/10.1093/annonc/mdl300
  3. Fennell DA, Gaudino G, O'Byrne KJ, Mutti L, van Meerbeeck J (2008). Advances in the sysytemic therapy of malignant pleural mesothelioma. Nat Clin Pract Oncol, 5, 136-47.
  4. Horgan AM, Yang B, Azad AK, et al (2011). Pharmacogenetic and germline prognostic markers of lung cancer. J Thorac Oncol, 6, 296-304. https://doi.org/10.1097/JTO.0b013e3181ffe909
  5. Joerger M, Dejong D, Burylo A, et al (2011). Tubuline, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non small-cell lung cancer receiving first-line platinum-gemcitabine chemotherapy. Lung Cancer, 74, 31-7.
  6. Kapoor S (2013). ERCC1 and its role in tumor pathogenesis and progression. Urol Oncol, 31, 280-5. https://doi.org/10.1016/j.urolonc.2012.10.010
  7. Lee KH, Min HS, Han SW, et al (2008). ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer. Lung Cancer, 60, 401-7. https://doi.org/10.1016/j.lungcan.2007.10.014
  8. Li Y, Huang XE, Jin GF, et al (2011). Lack of any relationship between chemotherapy toxicity in non-small cell lung cancer cases and polymorphisms in XRCC1 codon 399 or XPD codon 751. Asian Pac J Cancer Prev, 12, 739-42.
  9. Li FY, Ren XB, Xie XY, Zhang J (2013a). Meta-analysis of excision repair cross-complementation group 1 (ERCC1) association with response to platinum-based chemotherapy in ovarian cancer. Asian Pac J Cancer Prev, 14, 7203-6. https://doi.org/10.7314/APJCP.2013.14.12.7203
  10. Li XD, Han JC, Zhang YJ, et al (2013b). Common variations of DNA repair genes are associated with response to platinumbased chemotherapy in NSCLCs. Asian Pac J Cancer Prev, 14, 145-8. https://doi.org/10.7314/APJCP.2013.14.1.145
  11. Martin LP, Hamilton TC, Schilder RJ (2008). Platinum resistance: the role of DNA repair pathways. Clin Cancer Res, 14, 1291-5. https://doi.org/10.1158/1078-0432.CCR-07-2238
  12. Metintas S, Metintas M, Ucgun I, Oner U (2002). Malignant mesothelioma due to environmental exposure to asbestos: Follow-up of a Turkish cohort living in a rural area. Chest, 122, 2224-9. https://doi.org/10.1378/chest.122.6.2224
  13. Olaussen KA, Dunant A, Fouret P, et al (2006). DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med, 355, 983-91. https://doi.org/10.1056/NEJMoa060570
  14. Ozkan M, Akbudak IH, Deniz K, et al (2010). Prognostic value of excision repair cross-complementing gene 1 expression for cisplatin-based chemotherapy in advanced gastric cancer. Asian Pac J Cancer Prev, 11, 181-5.
  15. Pagan V, Ceron L, Paccagnella A, Pizzi G (2006). 5-year prospective results of trimodality treatment for malignant pleural mesothelioma. J Cardiovasc Surg, 47, 595-601.
  16. Pfeifer GP, Denissenko MF, Olivier M, et al (2002). Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene, 21, 7435-51. https://doi.org/10.1038/sj.onc.1205803
  17. Righi L, Papotti MG, Ceppi P, et al (2010). Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexedbased chemotherapy. J Clin Oncol, 28, 1534-9. https://doi.org/10.1200/JCO.2009.25.9275
  18. Santoro A, O'Brien ME, Stahel RA, et al (2008). Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaive patients with malignant pleural mesothelioma: results of the international expanded access program. J Thorac Oncol, 3, 756-63. https://doi.org/10.1097/JTO.0b013e31817c73d6
  19. Simon GR, Sharma S, Cantor A, Smith P, Bepler G (2005). ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest, 127, 978-83. https://doi.org/10.1378/chest.127.3.978
  20. Zhang ZY, Tian X, Wu R, et al (2012). Predictive role of ERCC1 and XPD genetic polymorphisms in survival of Chinese non-small cell lung cancer patients receiving chemotherapy. Asian Pac J Cancer Prev, 13, 2583-6. https://doi.org/10.7314/APJCP.2012.13.6.2583
  21. Zhang YY, Gu KS (2013). DNA repair capacity in peripheral blood lymphocytes predicts efficacy of platinum-based chemotherapy in patients with gastric cancer. Asian Pac J Cancer Prev, 14, 5507-12. https://doi.org/10.7314/APJCP.2013.14.9.5507
  22. Zimling ZG, Sorensen JB, Gerds TA, et al (2012). Low ERCC1 expression in malignant pleural mesotheliomas treated with cisplatin and vinorelbine predicts prolonged progression-free survival. J Thorac Oncol, 7, 249-56. https://doi.org/10.1097/JTO.0b013e318233d6a9

Cited by

  1. Malignant pleural mesothelioma: diagnostic value of medical thoracoscopy and long-term prognostic analysis vol.18, pp.1, 2018, https://doi.org/10.1186/s12890-018-0619-3